| Purpose : To observe the clinical efficacy of Shenling Baizhu Powder combined with Mesalazine in the treatment of mild to moderate ulcerative colitis with syndrome of dampness stagnancy due to spleen deficiency to evaluate the clinical effectiveness and safety of this protocol,and provide new research ideas and methods for modern medicine for ulcerative colitis treatment.The experimental method : Patient information collection,which was diagnosed as mild to moderate ulcerative colitis with syndrome of dampness stagnancy due to spleen deficiency from July 2020 to October 2021 were collected from the Anorectal Department of Hubei Hospital of Traditional Chinese Medicine Guanggu hospital district.The patients were randomly divided into experimental group（Shenling Baizhu Powder combined with Mesalazine Enteric-coated Tablets）and control group（Compound glutamine enteric-soluble capsule combined with Mesalazine Enteric-coated Tablets）,31 cases in each group.The experimental group was given Shenling Baizhu powder decoction（1 dose a day,divided into morning and evening,with warm water 200 ml each time）combined with Mesalazine Enteric-coated Tablets（4times a day,1g each time）,and the control group was treated with compound glutamine enteric-soluble capsules（3 tablets each time,3 times a day） combined with mesalazine enteric-soluble tablets（4 times a day,1g each time）.The treatment period of the experimental group and the control group was 3 months.After treatment,the two groups were compared to observe the indicators of TCM single symptom score,TCM syndrome efficacy,total clinical efficacy,Modified Mayo Clinic score,IBDQ score and drug safety evaluation before and after treatment.The research conclusion:（1）The results of this study showed that the experimental group and the control group were improved in 7 TCM symptoms including passing stool with pus and blood,abdominal distention,diarrhea,abdominal pain,passing tenesmus,fatigue and poor appetite（Р<0.05）.And the experimental group in the improvement of abdominal distension,diarrhea,abdominal pain,tenesmus,fatigue and poor appetite effect is significantly better than the control group（Р<0.05）,however,there was no statistically significant improvement in the efficacy of the experimental group in improving passing stool with pus and blood compared with the control group（Р>0.05）.（2）Comparison of TCM syndrome and curative effect between the two groups,the total effective rate of experimental group and control group was96.7% and 80.6%,Z=2.646,P=0.008<0.05,it can be seen that there are differences between the two groups,and the therapeutic effect of TCM syndrome in the experimental group is significantly better than that in the control group.（3）In terms of total clinical efficacy,the effective rates of treatment group and control group were 96.7% and 77.4%,Z=-2.498,P=0.013<0.05,it can be concluded that there are significant differences between the two groups,indicating that the total clinical efficacy of the experimental group is better than the control group.（4）After treatment,Mayo score in both groups was significantly lower than before treatment（P<0.05）,It can be seen that drug intervention in both groups can improve the condition of UC patients;by comparing the two groups after treatment,the modified Mayo Score of the experimental group was significantly lower than that of the control group（P<0.05）,indicating that the experimental group was significantly better than the control group in controlling UC disease activity.（5）After treatment,IBDQ scores of patients in both groups increased compared with before treatment（P<0.05）,indicating that drugs in both groups can improve the quality of life of patients with UC.The IBDQ score of the control group was significantly lower than that of the experimental group（P=0.01<0.05）.The results showed that the experimental group was better than the control group in improving the quality of life of patients.（6）Patients in both groups had stable vital signs and no adverse drug reactions or side effects during treatment.After treatment,electrocardiogram,blood routine examination,urine routine examination,liver and kidney function,electrolyte and coagulation of the patient were not significantly abnormal.The experimental conclusion:（1）Shenling Baizhu Powder combined with Mesalazine Enteric-coated Tablets and Compound glutamine enteric-soluble capsule combined with Mesalazine Enteric-coated Tablets are both effective in the treatment of mild to moderate UC with syndrome of dampness stagnancy due to spleen deficiency.（2）Shenling Baizhu Powder combined with Mesalazine Enteric-coated Tablet is superior to compoundglutamine enteric-coated capsule combined with mesalazine enteric-coated tablet in the treatment of mild to moderate spleen deficiency and dampness-induced UC in terms of TCM symptoms,TCM syndrome efficacy,total clinical efficacy,UC disease activity and quality of life of patients.（3）Shenling Baizhu Powder combined with Mesalazine Enteric-coated Tablets has obvious application effect in the treatment of mild to moderate UC of further exploration and promotion by clinicians. |
PDF Full Text Request